Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeffrey Wu is active.

Publication


Featured researches published by Jeffrey Wu.


Neurosurgery | 2012

Accelerator-based stereotactic radiosurgery for brainstem metastases.

Chun-Shu Lin; Michael T. Selch; Steve P. Lee; Jeffrey Wu; Furen Xiao; David S. Hong; Chien-hua Chen; Aamir Hussain; Percy Lee; Antonio A.F. De Salles

BACKGROUND: Stereotactic radiosurgery represents a noninvasive alternative treatment for intracranial metastases. OBJECTIVE: To investigate the treatment outcome of linear accelerator-based stereotactic radiosurgery (linac-SRS) for brainstem metastases. METHODS: We retrospectively reviewed our database of patients who were diagnosed with brainstem metastases and underwent linac-SRS between 1997 and 2008 at the University of California, Los Angeles. RESULTS: A total of 45 patients with 48 brainstem metastases were treated. The median target volume was 0.40 mL (range, 0.02-5.70 mL), and median prescription dose was 14 Gy (range, 10-17 Gy) at 90% isodose curve. The median survival time was 11.6 months. Longer survival time was associated with higher Karnofsky performance status. The local control rate was 92% at 6 months and 88% at 1 year. Univariate analysis demonstrated a significant relationship between local control and tumor volume (⩽0.4 mL vs >0.4 mL, P = .023) and SRS mode (conventional circular arc vs dynamic conformal arc, P = .044). There was a trend toward improved local control and prescription dose >14 Gy (P = .059). Two patients had brainstem complications following treatment, and the complication rate was 4.7% at 2 years. Serious morbidity occurred with 17 Gy. CONCLUSION: Linac-SRS using a median dose of 14 Gy provided excellent local control in patients with brainstem metastases less than 0.4 mL with relatively low serious morbidity. The results of the study support the use of linac-SRS for patients with brainstem metastases. We advocate 14 to 16 Gy, given the high local control rate and low complication rate with this dose.


International Journal of Radiation Oncology Biology Physics | 2011

Ocular Response of Choroidal Melanoma With Monosomy 3 Versus Disomy 3 After Iodine-125 Brachytherapy

Omkar S. Marathe; Jeffrey Wu; Steve P. Lee; Fei Yu; Barry L. Burgess; Min Y. Leu; Bradley R. Straatsma; Tara A. McCannel

PURPOSE To report the ocular response of choroidal melanoma with monosomy 3 vs. disomy 3 after (125)I brachytherapy. METHODS AND MATERIALS We evaluated patients with ciliochoroidal melanoma managed with fine needle aspiration biopsy immediately before plaque application for (125)I brachytherapy between January 1, 2005 and December 31, 2008. Patients with (1) cytopathologic diagnosis of melanoma, (2) melanoma chromosome 3 status identified by fluorescence in situ hybridization, and (3) 6 or more months of follow-up after brachytherapy were sorted by monosomy 3 vs. disomy 3 and compared by Kruskal-Wallis test. RESULTS Among 40 ciliochoroidal melanomas (40 patients), 15 had monosomy 3 and 25 had disomy 3. Monosomy 3 melanomas had a median greatest basal diameter of 12.00 mm and a median tumor thickness of 6.69 mm before brachytherapy; at a median of 1.75 years after brachytherapy, median thickness was 3.10 mm. Median percentage decrease in tumor thickness was 48.3%. Disomy 3 melanomas had a median greatest basal diameter of 10.00 mm and median tumor thickness of 3.19 mm before brachytherapy; at a median of 2.00 years after brachytherapy, median tumor thickness was 2.37 mm. The median percentage decrease in tumor thickness was 22.7%. Monosomy 3 melanomas were statistically greater in size than disomy 3 melanomas (p < 0.001) and showed a greater decrease in tumor thickness after brachytherapy (p = 0.006). CONCLUSION In this study, ciliochoroidal melanomas with monosomy 3 were significantly greater in size than disomy 3 melanoma and showed a significantly greater decrease in thickness at a median of 1.75 years after brachytherapy. The greater decrease in monosomy 3 melanoma thickness after brachytherapy is consistent with other malignancies in which more aggressive pathology has been shown to be associated with a greater initial response to radiotherapy.


Rare Tumors | 2011

Pineocytoma with diffuse dissemination to the leptomeninges

Caitlin Gomez; Jeffrey Wu; Whitney B. Pope; Harry V. Vinters; Antonio DeSalles; Michael T. Selch

Pineal parenchymal tumors are rare. Of the three types of pineal parenchymal tumors, pineocytomas are the least aggressive and are not known to diffusely disseminate. In this paper, we report the successful treatment of a case of pineocytoma with diffuse leptomeningeal relapse following initial stereotactic radiotherapy. A 39-year-old female presented with headaches, balance impairment, urinary incontinence, and blunted affect. A pineal mass was discovered on magnetic resonance imaging (MRI). A diagnosis of pineocytoma was established with an endoscopic pineal gland biopsy, and the patient received stereotactic radiotherapy. Ten years later, she developed diffuse leptomeningeal dissemination. The patient was then successfully treated with craniospinal radiation therapy. Leptomeningeal spread may develop as late as 10 years after initial presentation of pineocytoma. Our case demonstrates the importance of long-term follow-up of patients with pineal parenchymal tumors following radiation therapy, and the efficacy of craniospinal radiation in the treatment of leptomeningeal dissemination.


The Annals of Thoracic Surgery | 2006

Cardiac Surgery in Children With End-Stage Liver Disease Awaiting Liver Transplantation

Jonah Odim; Jeffrey Wu; Hillel Laks; Anamika Banerji; Stacey Drant


International Journal of Radiation Oncology Biology Physics | 2009

Monte Carlo vs. Pencil Beam Algorithm with and without Tissue Heterogeneity Correction in Stereotactic Body Radiation Therapy for Lung Tumors

Jeffrey Wu; Chul Lee; Nzhde Agazaryan; S. Tenn; Michael L. Steinberg; Michael T. Selch; Percy Lee


International Journal of Radiation Oncology Biology Physics | 2018

A prospective phase II study evaluating safety and efficacy of combining stereotactic body radiation therapy with heat-based ablation for centrally located lung tumors

Kiri A. Sandler; Fereidoun Abtin; Robert D. Suh; Ryan Cook; Carol Felix; Jay Lee; Edward B. Garon; Jeffrey Wu; Elaine Luterstein; Nzhde Agazaryan; Stephen Tenn; Chul Lee; Michael L. Steinberg; Percy Lee


International Journal of Radiation Oncology Biology Physics | 2017

Oral Scientific SessionsResults from a Prospective Phase 2 Trial Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy with Radiofrequency Ablation for Centrally Located Lung Tumors

P. Lee; Kiri A. Sandler; Fereidoun Abtin; Robert D. Suh; Carol Felix; Jay Lee; Edward B. Garon; Jeffrey Wu; Nzhde Agazaryan; S. Tenn; Christopher J. Lee; Michael L. Steinberg


International Journal of Radiation Oncology Biology Physics | 2014

Early Outcomes from a Prospective Phase II Trial Evaluating Safety and Efficacy of Combining SBRT with RFA for Centrally Located Lung Tumors

Percy Lee; Carol Felix; Fereidoun Abtin; Jeffrey Wu; Robert D. Suh; S. Tenn; Christopher J. Lee; Pin-Chieh Wang; Jay M. Lee; Edward B. Garon; V. Basehart; Nzhde Agazaryan; Michael L. Steinberg


Management of Cancer in the Older Patient | 2012

Chapter 7 – Radiation Therapy for the Older Patient

Jeffrey Wu; Susan A. McCloskey; Michael L. Steinberg


International Journal of Radiation Oncology Biology Physics | 2012

Safety and Efficacy of Stereotactic Body Radiation Therapy for Pulmonary Metastases From High-Grade Sarcomas

Niraj Mehta; Michael T. Selch; Noah Federman; Bartoz Chmielowski; Jay M. Lee; Fritz C. Eilber; Pin-Chieh Wang; Jeffrey Wu; Nzhde Agazaryan; Percy Lee

Collaboration


Dive into the Jeffrey Wu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Percy Lee

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carol Felix

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert D. Suh

University of California

View shared research outputs
Top Co-Authors

Avatar

S. Tenn

University of California

View shared research outputs
Top Co-Authors

Avatar

Steve P. Lee

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge